Dexcom G6 Joins Forces with Omnipod®
Dexcom G6 Continuous Glucose Monitoring (CGM) System and Omnipod 5 Automated Insulin Delivery System are better together because they can help keep you in range1, without tubes, daily injections or fingersticks!*
*Fingersticks required for diabetes treatment decision if symptoms or expectations do not match readings.
Why Dexcom G6 + Omnipod® 5 are better together
- Dexcom G6 is a highly accurate1, small wearable that continuously tracks your glucose and sends the data to a smart device‡ every five minutes – without the use of fingersticks*.
- Omnipod® leads the charge in tubeless insulin delivery and now offeres the only tubeless automated insulin delivery system compatible with Dexcom G6. When paired together, they communicate around the clock, using your glucose value and trend to automatically deliver insulin as needed – creating a hybrid closed-loop system.
* Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
Get the insight you need to spend more Time in Range
Seeing your numbers in real time helps you understand how diet, exercise, and even stress affect your glucose. So, you can gain real insight and make small adjustments that have a big impact.
Tubeless automated insulin delivery, simplified
Omnipod® 5 is the first and only tubeless system to automatically adjust insulin delivery based on your personal needs, helping to prevent highs and lows†. It's the system that never sleeps.
Keeps you in glycemic range, day and night
Set your own glucose alerts to notify you before you're too high or too low. The Urgent Low Soon Alert can warn you up to 20 minutes before a low - even at night.
Seamless integration
1. Dexcom G6 – The wearable sensor takes glucose measurements and sends those numbers to your Pod and/or smart device‡ to let you know your current glucose numbers.
2. Pod – Tubeless, wearable, and waterproof**, the state-of-the-art Pod, with built-in SmartAdjust™ technology, sits right on your body and automatically adjusts insulin delivery based on your CGM readings to help keep you in range†.
3. Smart Device – Take full control of the entire system by viewing your glucose data in real time from your compatible smart device‡.
Bean's Betes
Dexcom Warrior
Dexcom Warrior
Get started today
Dexcom G6 and Omnipod® 5 are amazing on their own, but if you aren't using them together, then you're simply missing out. Follow the steps below to get going.
New Patients: Get Started with Dexcom CGM
Please fill out the form below to help us determine if the Dexcom CGM System is right for you or your loved one. A customer service representative of Dexcom, or a service provider on behalf of Dexcom, may follow up with you to process a full insurance benefits check or to discuss other Dexcom products, services or programs, after reviewing your information.
Personal & Diabetes Information
All fields marked with an asterisk (*) are required.
Have Questions?
* If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
**The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.
† Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 128 participants with T1D aged 14-70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001.
‡ For a list of compatible devices, visit www.dexcom.com/compatibility1 Brown SA, et al. Diabetes Care. 2021:dc210172.;
2 Beck, RW. JAMA. 2017; 317(4); 371-378.
3 Welsh JB, et al. Diabetes Technol Ther. 2019;21(3):128-132.
**The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.
† Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 128 participants with T1D aged 14-70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001.
‡ For a list of compatible devices, visit www.dexcom.com/compatibility1 Brown SA, et al. Diabetes Care. 2021:dc210172.;
2 Beck, RW. JAMA. 2017; 317(4); 371-378.
3 Welsh JB, et al. Diabetes Technol Ther. 2019;21(3):128-132.